# Ollin Biosciences Raises $330M Series B to Launch Phase 3 Trials for VEGF/Ang2 Bispecific Antibody

> financing · REPORTED · 2026-06-24

Ollin Biosciences closed a $330 million Series B on approximately June 24, 2026, six months after early trial data showed its VEGF/Ang2 bispecific antibody OLN324 outperformed Genentech's Vabysmo in wet AMD. The company plans to launch at least three Phase 3 trials with OLN324, supported by investors including T. Rowe Price, Mubadala Capital, and Monograph Capital.

- Company: Ollin Biosciences
- Sector: therapeutics
- Primary source: https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.